Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer

Optimum的首席研究人员开发了肿瘤穿透微粒(TPM)，这是一种一流的递送系统，专为腹膜腔的独特解剖特性量身定做。热塑性弹性体是一种多组分、多功能、生物相容性、可生物降解、可控释的微米级聚合物微粒。TPMS旨在靶向、穿透并将药效学优化的药物水平输送到腹膜肿瘤的浅层和深层。TPMS是一种递送平台，可用于递送小分子疗法、生物制剂、基因载体和显像剂。第一代TPM(TPM001)含有紫杉醇，胰腺癌是第一个适应症。其目标是开发一种有效的治疗方法来局部控制转移性胰腺癌，更广泛地说，是腹膜肿瘤。 Bridgs团队在完成以下关于TPM001的研究方面取得了进展： -制造良好制造规范(GMP)药品 -配方开发 -药代动力学/吸收、分布、代谢和排泄(PK/ADME)研究 -研究新药(IND)指导的毒理学

The lead investigators at Optimum developed tumor-penetrating microparticles (TPMs), a first-in-class delivery system tailored to the unique anatomical properties of the peritoneal cavity. TPMs are multicomponent, multifunctional, biocompatible, biodegradable, controlled-release polymeric micron-size particles. TPMs are designed to target, penetrate and deliver pharmacodynamically optimized drug levels to the superficial and deep layers of peritoneal tumors. TPMs represent a delivery platform that can be used to deliver small molecule therapeutics, biologics, gene vectors and imaging agents. The first generation TPM (TPM001) is loaded with paclitaxel, with pancreatic cancer as the first indication. The goal is to develop an effective treatment for locoregional control of metastatic pancreatic cancer and, more generally, peritoneal tumors. The BrIDGs team has made progress towards the completion of the following studies on TPM001: - Manufacture of Good Manufacturing Practice (GMP) drug product - Formulation development - Pharmacokinetic/absorption, distribution, metabolism, and excretion (PK/ADME) studies - Investigational New Drug (IND)-directed toxicology